



Faculty of Science  
Chemistry Department

## SYNTHESIS OF SOME NEW COUMARIN DERIVATIVES AND STUDY THEIR ANTITUMOR ACTIVITY

Thesis submitted By

**Ahmed Sabt Ibrahim Mohamed**

Assistant Researcher, Chemistry of Natural Compounds Department  
National Research Center

For the Degree of  
Doctor of Philosophy [Ph.D]  
(In Chemistry)

### Under Supervision

**Prof. Dr. Hassan M. F. Madkour**  
Professor of Organic Chemistry  
Faculty of Science  
Ain Shams University

**Prof. Dr. Omailma Mohamed Abd Elhafez**  
Professor of Natural Products Chemistry  
Chemistry of Natural Compounds Department  
National Research Center

**Prof. Dr. Ezz El-Din A. M. El-Khrisy**  
Professor of Natural Products Chemistry  
Chemistry of Natural Compounds  
Department National Research Center

Chemistry Department  
Faculty of Science  
Ain Shams University  
2018

## *Approval Sheet*

### **Synthesis of some new coumarin derivatives and study their antitumor activity**

**Name of Candidate: Ahmed Sabt Ibrahim Mohamed**

This thesis has been approved for submission by supervisors:

**Prof. Dr. Hassan M. F. Madkour**

*Faculty of Science-Ain Shams University*

.....

**Prof. Dr. Omaila Mohamed Abd Elhafez**

*Chemistry of Natural Compounds Department- National Research Center*

.....

**Prof. Dr. Ezz El-Din A. M. El-Khrisy**

*Chemistry of Natural Compounds Department- National Research Center*

.....

Head of Chemistry Department

**Prof.Dr. Ibrahim Hosnsiny Ali Bader**

## **ACKNOWLEDGEMENT**

***First of all, I would like to extend due praise and thanks to ALLAH that this work has been completed.***

I would like to express my sincere gratitude to **Prof.Dr. Hassan M. F. Madkour**, Professor of Chemistry Department, *Faculty of Science, Ain Shams University* for his continuous supervision, encouragement and kind support during the course of the present investigation.

My endless appreciation to **Prof. Dr. Omaima Mohamed Abd Elhafez**, Professor of Natural Products Chemistry, Chemistry of Natural Compounds Department, National Research Centre for suggesting the point of research, constructive supervision, and her great support, faithful advice and unlimited efforts in this research.

I am also deeply grateful to **Prof. Dr. Ezz El-Din A. M. El-Khrisy** Professor of Natural Products Chemistry, Chemistry of Natural Compounds Department, National Research Centre for his kind supervision, valuable advices and encouragement through the work.

I wish to express my great thanks and appreciation to **Dr. Radwan S. El-Haggar**, Assistant professor Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, for his fruitful contribution in this work. **Dr. Radwan** designed, carried out and interpreted the outcomes data of the biological evaluations.

Sincere thanks to **Dr. Wagdy M. Eldehna**, Lecturer of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University for carrying out Quantitative Structure activity relationship (QSAR).

I would like to express my thanks and appreciation to **prof. Dr. Laila. A. Rashed**, Professor of biochemistry and molecular biology, Department of

Biochemistry, Faculty of Medicine, Cairo University, for carrying out the *In vitro* cancer cell lines Studies

Words couldn't help me in expressing my deep appreciation to ***Professor Harri Lönnberg and Dr. Mikko Ora*** at University of Turku and Åbo Akademi University, Finland, for hosting me 8 months at his group and kind help me to complete synthesis part from my thesis. Also, I am grateful to Prof. Dr. ***Daniel Abankwa***. Professor of Åbo Akademi university, Finland for carrying biology of K-ras.

I am thankful to all my colleagues at Chemistry of Natural Compounds Department- National Research Centre for emotional support and encouragement during completion of this work.

I would like to give my special thanks to **my wife, my mother and my brother** for the patience and moral support they provided throughout my research work.

***Sincerely***  
***Ahmed Sabt***

# Contents

|   | <b>Page</b> |
|---|-------------|
| <b>List of abbreviations</b> .....                            | <b>i</b>    |
| <b>Abstract</b> .....   | <b>ii</b>   |
| <b>Summary</b> .....  | <b>iv</b>   |
| <b>Introduction</b> .....                                     | <b>1</b>    |
| <b>i. Coumarin</b> .....                                      | <b>1</b>    |
| <b>a) Natural sources of coumarin</b> .....                   | <b>1</b>    |
| <b>b) General methods for the synthesis of coumarin</b> ..... | <b>3</b>    |
| <b>c) Biosynthetic pathway of coumarin</b> .....              | <b>11</b>   |
| <b>ii. Reactivity of coumarins</b> .....                      | <b>12</b>   |
| <b>iii. Biological activity of coumarin</b> .....             | <b>18</b>   |
| <b>iv. Anticancer Activity of coumarin</b> .....              | <b>19</b>   |
| <b>v. Cancer</b> .....  | <b>27</b>   |
| <b>vi. The biology of ras</b> .....                           | <b>28</b>   |
| <b>Theoretical discussion</b> .....                           | <b>34</b>   |
| <b>Biological screening</b> .....                             | <b>71</b>   |
| <b>Figures</b> .....  | <b>103</b>  |
| <b>Experimental work</b> .....                                | <b>168</b>  |
| <b>References</b> .....                                       | <b>193</b>  |
| <b>Arabic summary</b> .....                                   | <b>i</b>    |

## List of Abbreviations

|                                 |  |
|---------------------------------|--|
| <b>Arg</b>                      | Arginine (R)   |
| <b>Arl2</b>                     | The ADP-ribosylation factor-like 2(release factor)           |
| <b>DCM</b>                      | Dichloromethane  |
| <b>DMSO</b>                     | Dimethylsulfoxide  |
| <b>DMTrCl</b>                   | 4,4- Dimethoxytrityl chloride                                |
| <b>EtOAc</b>                    | Ethylacetate   |
| <b>FLIM</b>                     | Fluorescence lifetime microscopy                             |
| <b>FRET</b>                     | Forster resonance energy transfer                            |
| <b>FTase</b>                    | Farnesyl transferase enzyme                                  |
| <b>FTI</b>                      | Farnesyl transferase inhibitors                              |
| <b>GAPs</b>                     | GTPase activating proteins                                   |
| <b>GEFs</b>                     | Guanine nucleotide exchange factors                          |
| <b>Glu</b>                      | Glutamate (E)  |
| <b>HEK</b>                      | Human Embryonic Kidney                                       |
| <b>HRMS</b>                     | High resolution mass   |
| <b>HVR</b>                      | C-terminal hypervariable region                              |
| <b>IC<sub>50</sub></b>          | The half maximal inhibitory concentration                    |
| <b>k-ras</b>                    | Kirsten rat sarcoma viral oncogene                           |
| <b>MAPK</b>                     | Mitogen-activated protein kinase                             |
| <b>Met</b>                      | Methionine (M)   |
| <b>PDB</b>                      | Protein Data Bank  |
| <b>PDE<math>\delta</math></b>   | Delta subunit of the phosphodiesterase 6                     |
| <b>PI3K</b>                     | phosphatidylinositol 3-kinase                                |
| <b>QSAR</b>                     | Quantitative structure activity relationship                 |
| <b>Ras</b>                      | Rat sarcoma (protein)  |
| <b>RMSD</b>                     | Root mean standard deviation                                 |
| <b>SRB</b>                      | Sulforhodamine B   |
| <b>siPDE<math>\delta</math></b> | Specific inhibitors Delta subunit of the phosphodiesterase 6 |
| <b>TEA</b>                      | Triethylamine  |
| <b>THF</b>                      | Tetrahydrofurane   |
| <b>Tyr</b>                      | Tyrosine (Y)   |

## Abstract

**Name:** Ahmed Sabt Ibrahim Mohamed

**Title:** Synthesis of some new coumarin derivatives and study their antitumor activity

Coumarin was subjected to chlorosulfonation *via* chlorosulfonic acid to yield coumarin-6-sulfonylchloride **1** which was utilized as a key intermediate to prepare new series from coumarin-6-sulfonamides derivatives. Therefore, compound **1** was refluxed in ethanol with sulfanilamide, pyridine sulfanilamide and/or 4-aminoacetophenone to afford the corresponding coumarin-6-sulfonamides **2 - 4**, respectively. N-(4-acetylphenyl)-2-oxo-2*H*-chromene-6-sulfonamide **4** reacted with phenylhydrazine derivatives in absolute ethanol and triethylamine to afford **5a-c**. On the other hand, when compound **4** reacted with *p*-toluene sulfonylhydrazide, compound **6** was isolated. When compound **4** was refluxed with thiosemicarbazide in the presence of ethanol and acetic acid, the thiosemicarbazone **7** was obtained.

The reaction of thiosemicarbazone **7** with chloroacetone, ethyl-2-chloroacetoacetate, hydrozoylchlorides-*p*-Cl and *p*-CH<sub>3</sub>, phenylbromide and/or 3-(2-bromoacetyl)-2*H*-chromen-2-one under reflux condition in dioxane and triethylamine gave the corresponding coumarinthiazole derivative **8-12**, respectively. Also, thiazolidinone derivatives were obtained *via* reaction of thiosemicarbazone **7** with bromoacetic acid and/or 2-bromopropanoic to afford the thiazolidinone derivatives **13** and **14**, respectively.

2-((6-hydroxyhexyl)oxy)isoindoline-1,3-dione **15** reacted with 4,4-dimethoxy trityl chloride (DMTrCl) in dry pyridine to give **16**.

Compound **16** stirred with hydrazine hydrate at room temperature to give *O*-6-dimethoxytritylatedhexylhydroxylamine **17**. 3-acetylcoumarin condensed with compound **17** in the presence of ethanol and pyridine to yield coumarin *O*-alkyl oximetrityl **18** and a subsequent conversion to **19** *via* the acid catalyzed detritylation process. Phosphitylation of **19** *via* three steps to give final product **20**. by similar way compound **4** reacted with aminoxy and then Phosphitylation to afford compound **23**.

Moreover, 6-bromohexanol **24** reacted with tritylchloride in pyridine yielded 6-bromotrityl **25**. The later was subjected to react with 4-hydroxycoumarin to afford compound **26**. Detritylation of compound **26** and then Phosphitylation to convert to the final target **28**.

Coumarin-3-carboxylate **29** was allowed to reflux with 6-aminohexanol in the presence of ethanol and piperidine as a catalyst and afforded coumarin-3-carboxamide **30**. Compound **30** subjected to Phosphitylation process to yield final target **31**.

The newly synthesized compounds **2-14** were evaluated for their anti-proliferative activity against three human tumor cell lines HepG2, CaCo and MCF-7. The most active compounds **11** and **13** were further studied for their apoptosis inducing properties. a 2D-QSAR model was performed on these synthesized compounds. also, the four final compounds from **20**, **23**, **28** and **31** were evaluated as potent KRAS-PDE $\delta$  interaction inhibitors. Computational docking of the compounds into the PDE $\delta$  crystal structure was performed.

**Key words:** Synthesis, Coumarin derivatives, Phosphitylation, apoptosis, anti-proliferative activity and k-ras.

## SUMMARY

The present research work aimed to synthesize new series of coumarin-6-sulfonamides bearing Schiff's bases, thiazole or thiazolidinone moieties. In addition the coumarins derivatives linked to the protected phosphate moiety *via* a hexyl hydrocarbon chain were prepared. All the target compounds were subjected to antitumor activity assessment. Moreover, molecular docking and quantitative structure-activity relationship were performed to help the experts to better predict the possible activity of target compounds.

Coumarin was subjected to chlorosulfonation by chlorosulfonic acid yielded coumarin-6-sulfonylchloride **1** which was utilized as a key intermediate to prepare new series from coumarin-6-sulfonamides derivatives. Therefore, compound **1** was refluxed in ethanol in presence of glacial acetic acid with sulfanilamide and/or pyridine sulfanilamide to afford the corresponding coumarin-6-sulfonamides **2** and **3**, respectively. Coumarin-6-sulfonylchloride **1** was allowed to react with 4-aminoacetophenone in presence of dichloromethane and pyridine to yield N-(4-acetylphenyl)-2-oxo-2*H*-chromene-6-sulfonamide **4** [cf. scheme 1].

Moreover, Schiff's bases derivatives were prepared *via* condensation of N-(4-acetylphenyl)-2-oxo-2*H*-chromene-6-sulfonamide **4** with phenylhydrazine derivatives in absolute ethanol and triethylamine to afford **5a-c**. On the other hand, when compound **4** reacted with *p*-toluene sulfonylhydrazide, compound **6** was isolated. When compound **4** was refluxed with thiosemicarbazide in the presence of ethanol and acetic acid,

the thiosemicarbazone **7** was obtained [cf.scheme2].

The reaction of thiosemicarbazone **7** with chloroacetone under reflux condition in dioxane and triethylamine gave the methylthiazole derivative **8**. Also, when compound **7** was allowed to react with ethyl-2-chloroacetoacetate, the thiazolecarboxylate compound **9** was obtained. refluxing thiosemicarbazones **7** with different hydrozoylchlorides-p-Cl and p-CH<sub>3</sub>, it gave coumarinthiazole derivatives **10a** and **10b**[cf.scheme3].

When thiosemicarbazone **7** was allowed to react with phenylbromide in the presence of dioxane and triethylamine, compound **11** was isolated. Compound **7** reacted with 3-(2-bromoacetyl)-2*H*-chromen-2-one to give the thiazole derivative **12** [cf.scheme4]. Also, thiazolidinone derivatives were obtained *via* reaction of thiosemicarbazone **7** with bromoacetic acid and/or 2-bromopropanoic acid under reflux in acetic acid in the presence of an excess anhydrous NaOAc to afford the thiazolidinone derivatives **13** and **14**, respectively [cf.scheme 4].

Moreover, The newly synthesized compounds **2-14** were evaluated for their anti-proliferative activity against three human tumor cell lines HepG2 hepatocellular carcinoma, CaCo cancer and MCF-7 breast cancer. In particular, HepG2 cancer cell line was more susceptible to the synthesized derivatives. Compounds **11** and **13** ( $IC_{50} = 3.48 \pm 0.28$  and  $5.03 \pm 0.39 \mu M$ , respectively) were found to be the most potent derivatives against HepG2 being more active than doxorubicin ( $IC_{50} = 5.43 \pm 0.24$ ). In addition, compound **14** showed the most promising results against MCF-7 with  $IC_{50} = 10.62 \pm 1.35 \mu M$ . Moreover, cytotoxicity evaluation of the newly synthesized compounds in CaCo

revealed that compound **5a** exhibited significant antiproliferative activity with  $IC_{50}$  value  $8.53 \pm 0.72\mu M$ . Therefore, a 2D-QSAR model was performed on these synthesized compounds, to extract out the key regulatory features controlling the anticancer activity. The most active compounds **11** and **13** were further studied for their apoptosis inducing properties.

In the continuation of work, 2-((6-hydroxyhexyl)oxy)isoindoline-1,3-dione **15** reacted with 4,4-dimethoxytrityl chloride (DMTrCl) in dry pyridine and afforded 2-((6-(bis(4-methoxy phenyl) (phenyl) methoxy) hexyl)oxy)isoindoline-1,3-dione **16**. Compound **16** stirred with hydrazine hydrate at room temperature to give *O*-6-dimethoxytritylated hexylhydroxylamine **17** [cf.scheme5].

On the other hand, 3-acetylcoumarin condensed with compound **17** in the presence of ethanol and pyridine to yield coumarin *O*-alkyl oximetritryl **18** and a subsequent conversion to 3-(1-(((6-hydroxyhexyl) oxy) imino) ethyl)-2*H*-chromen-2-one **19** via the acid catalyzed detritylation process [cf.scheme5].

Phosphitylation of **19** with 1-chloro-*N,N*-diisopropyl-1-methoxyphosphinamine followed by tetrazole promoted displacement of the diisopropylamino ligand by 4-acylthio-2-hydroxymethyl-2-methyl-3-oxobutanoate and oxidation of the resulting phosphite triester to phosphate triester with iodine in THF/H<sub>2</sub>O/2,6-lutidine completed the synthesis to give final product **20** [cf.scheme5].


When compound **4** reacted with *O*-6-dimethoxytritylated hexylhydroxylamine **17**, *O*-alkyl oxime **21** was isolated. Compound **21** was stirred in dichloroacetic acid in presence of dichloromethane and afforded hydroxyhexylcoumarin **22**. Compound **22** was subjected to the phosphitylation process by using three steps to yield the target coumarinhexylphosphate **23**[**cf.scheme6**].

On the other hand, 6-bromohexanol **24** reacted with tritylchloride in pyridine yielded 6-bromotrityl **25**. The later was subjected to react with 4-hydroxycoumarin to afford compound **26**. Detritylation of compound **26** in the presence of dichloroacetic acid and dichloromethane gave coumarin-4-hydroxyhexyl **27**. Similarly, compound **27** was converted to the final target **28** *via* Phosphitylation [**cf.scheme7**].


Coumarin-3-carboxylate **29** was allowed to reflux with 6-aminohexanol in the presence of ethanol and piperidine as a catalyst and afforded coumarin-3-carboxamide **30**. Compound **30** reacted with 1-chloro-*N,N*-diisopropyl-1-methoxy phosphine amine followed by tetrazole promoted displacement of the diisopropylamino ligand by 4-acylthio-2-hydroxymethyl-2-methyl-3-oxobutanoate and oxidation of resulting phosphite triester to phosphate triester with iodine in THF/H<sub>2</sub>O/2,6-lutidine completed the synthesis to give final target **31** [**cf.scheme8**].

In order to demonstrate the validity of these reported research information, the synthesized target compounds were screened for their antitumor activity. Therefore, the four final compounds of coumarin linked to the protected phosphate moiety *via* a hexyl hydrocarbon chain (**20**, **23**, **28** and **31**) were evaluated as potent KRAS-PDE $\delta$  interaction inhibitors. Computational docking of the compounds into the PDE $\delta$


crystal structure was performed. Our model compound, Deltaflexin1, selectively disrupts K-Ras, but not H-Ras membrane organization. This selectivity profile is reflected in its anti-proliferative activity on breast and colorectal cancer cells.




Scheme 1



Scheme 2



Scheme 3



Scheme 4

